STENTYS CEO Gonzague Issenmann to present at Piper Jaffray 22nd Annual Health Care Conference

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)-- STENTYS (STNT.PA), a medical technology company that markets a new generation of innovative stents to treat Acute Myocardial Infarction (AMI), announced today that its CEO and co-founder, Gonzague Issenmann, has been invited to participate in the Piper Jaffray 22nd Annual Health Care Conference in New York City on Tuesday, November 30, 4:30 p.m. ET, at The New York Palace Hotel.

The company will be audio webcasting its presentation and interested parties can access the live presentation only at the company’s website or by clicking here.

STENTYS recently raised $31.9 million (€22.7 million) in an IPO on the NYSE Euronext Paris Stock Exchange; the proceeds will be used to commercialize its innovative stents for treating acute myocardial infarction (AMI) in Europe and to obtain regulatory approvals for their commercialization in the United States.

About STENTYS

Based in Princeton, N.J., and Paris, STENTYS has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., (also founder of CoreValve, which was acquired by Medtronic) and Gonzague Issenmann, STENTYS received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. STENTYS has commenced its marketing activities in several European countries.

This announcement is not an offer for sale of securities in the United States. The securities referred to herein have not been offered or sold in the United States and may not be offered or sold in the United States of America, except pursuant to a registration statement under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or pursuant to an exemption from registrations thereunder. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act.



CONTACT:

Ronald Trahan Associates Inc.
Ronald Trahan, APR, +1-508-359-4005, x108
President

KEYWORDS:   United States  Europe  North America  France  New Jersey  New York

INDUSTRY KEYWORDS:   Surgery  Health  Biotechnology  Cardiology  Medical Devices

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.